Analgesie postop
Analysis of individual patient data from clinical trials: epidural morphine for postoperative pain
+ Author Affiliations
- *Corresponding author. E-mail: andrew.moore@pru.ox.ac.uk
- Accepted September 10, 2009.
Abstract
Background Individual patient information from clinical trials is infrequently available, but can provide insights for clinical trials
and practice.
Methods We analysed
individual patient information from five randomized trials (913
patients) of i.v. patient-controlled analgesia
(IVPCA) plus epidural placebo, morphine sulphate
(MS) 5 mg, or extended-release epidural morphine (EREM; DepoDur™) at
doses
of 5–30 mg, to explore effects of a range of
epidural morphine doses. Pain and opioid requirement on first and second
postoperative
days, dose–response, clinically relevant
comparisons of IVPCA without epidural morphine, 5 mg MS, and 10 mg EREM,
and relationship
between patient rating and other measures were
described.
Results There were three
strong findings. Epidural morphine resulted in greater patient
satisfaction, despite higher rates of adverse
events. Those describing their analgesic medication
as ‘very good’ or ‘excellent’ used IVPCA opioid less and had pain
scores
significantly below the global mean, whereas those
describing their medication as ‘poor’ or ‘fair’ had pain scores
significantly
above the mean. Epidural morphine meant less need
for postoperative IVPCA opioid than epidural placebo. The therapeutic
gain
with EREM was lower pain scores with less IVPCA
opioid. Moderate or severe pruritus was more common with IVPCA plus
epidural
morphine, whatever the formulation, compared with
IVPCA plus placebo.
Conclusions Analysis of
individual patient data from high-quality clinical trials provides
important insights into characteristics of
new agents not immediately apparent from original
trials, and also informing clinical practice. Prophylactic epidural
morphine
provides a better patient experience than IVPCA
alone.
Commentaires
Enregistrer un commentaire